Ralph Baric

SKIP TO MAIN CONTENT About Us Admissions Degrees Students Departments Give SEARCH THE SITE NAVIGATE ACCESSIBILITY GILLINGS SCHOOL DIRECTORY Ralph S. Baric, PhD IN THIS SECTION CONTACT INFO Dr. Ralph Baric Ralph S. Baric, PhD WILLIAM R. KENAN, JR. DISTINGUISHED PROFESSOR DEPARTMENT OF EPIDEMIOLOGY PROFESSOR DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY MEMBER LINEBERGER COMPREHENSIVE CANCER CENTER T : (919) 966-3895 F : (919) 966-2089 E : rbaric@email.unc.edu 3304 Michael Hooker Research Building CB #7435 Chapel Hill, NC 27599 USA Curriculum Vitae Baric Laboratory (Twitter) Ralph Baric, PhD, is the William R. Kenan, Jr. Distinguished Professor in the Department of Epidemiology and Professor in the Department of Microbiology and Immunology. He is a Harvey Weaver Scholar from the National Multiple Sclerosis Society and an Established Investigator Awardee from the American Heart Association. In addition, he is a World Technology Award Finalist and a fellow of the American Association for Microbiology. He has spent the past three decades as a world leader in the study of coronaviruses and is responsible for UNC-Chapel Hill’s world leadership in coronavirus research. For these past three decades, Dr. Baric has warned that the emerging coronaviruses represent a significant and ongoing global health threat, particularly because they can jump, without warning, from animals into the human population, and they tend to spread rapidly. The Baric Lab uses coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence, pathogenesis, genetics and cross-species transmission. He has used alphavirus vaccine vectors to develop novel candidate vaccines. Dr. Baric has led the world in recognizing the importance of zoonotic viruses as a potentially rich source of new emerging pathogens in humans, with detailed studies of the molecular, genetic and evolutionary mechanisms that regulate the establishment and dissemination of such a virus within a newly adopted host. Specifically, he works to decipher the complex interactions between the virion and cell surface molecules that function in the entry and cross-species transmission of positive-strand RNA viruses. In 2017, 2018 and 2019, Dr. Baric was named to Clarivate Analytics’ Highly Cited Researchers list, which recognizes researchers from around the world who published the most widely-cited papers in their field. Also in 2017, he was awarded a grant for more than $6 million from the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate the development of a promising new drug in the fight against deadly coronaviruses, which is currently in clinical trials to reverse COVID-19 disease in humans. In this collaboration, he continued his partnership between the Gillings School and Gilead Sciences Inc. to focus on an experimental antiviral treatment that he had previously shown to prevent the development of severe acute respiratory syndrome coronavirus (SARS-CoV) in mice. The drug also was shown to inhibit MERS-CoV and multiple other coronaviruses (CoV), suggesting that it may actually inhibit all CoV. He continues to work with this drug. RALPH BARIC IN THE GILLINGS NEWS Researchers map how coronavirus infection travels through cells of nasal cavity and respiratory tract UNC researchers say COVID-19 treatment tocilizumab should be used with caution Gillings scientists study most potent neutralizing antibody against novel coronavirus to date Gillings researchers advance in the quest for a dengue vaccine UNC-based NC Policy Collaboratory to receive state funds to study and fight coronavirus Remdesivir, developed through a UNC-Chapel Hill partnership, proves effective against COVID-19 in NIAID human clinical trials A new antiviral drug heading into clinical trials offers hope for COVID-19 treatment — in part because it can be taken as a pill Watch Dr. Baric present at the 2018 Going Viral Symposium: Imagining the Next Flu Pandemic – and Preventing it! HONORS AND AWARDS William R. Kenan, Jr. Distinguished Professor of Epidemiology 2019, University of North Carolina at Chapel Hill Innovation Award for Faculty Research 2011, University of North Carolina at Chapel Hill Established Investigator Award 1994, American Heart Association Harvey Weaver Scholar 1986, National Multiple Sclerosis Society RESEARCH ACTIVITIES Most of the research in the Baric Lab uses coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence and cross-species transmission. Dr. Baric also has used alphavirus vaccine vectors to develop novel candidate vaccines. Zoonotic viruses represent a potentially rich source of new emerging pathogens in humans, yet little information is available concerning the molecular, genetic and evolutionary mechanisms that regulate the establishment and dissemination of such a virus within a newly adopted host. Dr. Baric's group utilizes molecular, genetic and biochemical approaches to decipher the complex interactions between the virion and cell surface molecules that function in the entry and cross-species transmission of positive-strand RNA viruses. RESEARCH INTEREST Infectious Disease KEY PUBLICATIONS An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. (2020). Sci Transl Med., pii: eabb5883.. View publication Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. (2020). Nat Commun., 11(1):222.. View publication Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination. Lindesmith LC, McDaniel JR, Changela A, Verardi R, Kerr SA, Costantini V, Brewer-Jensen PD, Mallory ML, Voss WN, Boutz DR, Blazeck JJ, Ippolito GC, Vinje J, Kwong PD, Georgiou G, Baric RS. (2019). Immunity, 50(6):1530-1541:e8. View publication Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform. Graham RL, Deming DJ, Deming ME, Yount BL, Baric RS. (2018). Commun Biol., 1:179.. View publication Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. (2017). Sci Transl Med., 9(396). pii: eaal3653.. View publication MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, Nicora CD, Purvine SO, Casey CP, Monroe ME, Weitz KK, Stratton KG, Webb-Robertson BM, Gralinski LE, Metz TO, Smith RD, Waters KM, Sims AC, Kawaoka Y, Baric RS (2018). Proceedings of the National Academy of Sciences, 115(5), E1012-E1021. Neutralization mechanism of a highly potent antibody against Zika virus. S Zhang, V Kostyuchenko, T Ng, X Lim, J Ooi, S Lambert, T Tan, D Widman, J Shi, R Baric, S Lok (2016). Nature communications, 7. SARS-like WIV1-CoV poised for human emergence. V Menachery, B Yount, A Sims, K Debbink, S Agnihothram, L Gralinski, R Graham, T Scobey, J Plante, S Royal, J Swanstrom, T Sheahan, R Pickles, D Corti, S Randell, A Lanzavecchia, W Marasco, R Baric (2016). Proceedings of the National Academy of Sciences of the United States of America. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. V Menachery, B Yount, K Debbink, S Agnihothram, L Gralinski, J Plante, R Graham, T Scobey, X Ge, E Donaldson, S Randell, A Lanzavecchia, W Marasco, Z Shi, R Baric (2015). Nature medicine, 21(12), 1508-13. Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial. Lisa Lindesmith, Martin Ferris, Clancy Mullan, Jennifer Ferreira, Kari Debbink, Jesica Swanstrom, Charles Richardson, Robert Goodwin, Frank Baehner, Paul Mendelman, Robert Bargatze, Ralph Baric (2015). PLoS Medicine, 12(3). EDUCATION Postdoctoral Fellowship, Microbiology, University of Southern California, 1986 PhD, Microbiology, North Carolina State University, 1982 BS, Zoology, North Carolina State University, 1977 RECENT NEWS This is the logo for the Patient-Centered Outcomes Research Institute (PCORI). PCORI funds UNC research to assess representativeness of COVID-19 treatment trials Flags from many countries flutter in the breeze. RESEARCH NEWS AJPH editorial: Populism threatens the public health response to COVID-19 Dr. Ralph Baric talks to Kendra Gully, a containment research specialist, at the Baric Lab. Common SARS-CoV-2 mutation may be more susceptible to vaccine This is the visual identity of the North Carolina Department of Health and Human Services’ COVID-19 Response. North Carolina has a new COVID-19 vaccination plan, and Dr. Leah Devlin helped write it! The UNC Gillings School professor co-chaired an advisory committee on the topic for the North Carolina Department of Health and Human Services. Find the full plan here: https://sph.unc.edu/sph-news/d… FEATURED EVENTS 2020 Norma Berryhill Distinguished Lecture November 17 @ 3:45 pm - 5:00 pm Environmental Sciences and Engineering Centennial Seminar featuring William Suk December 10 @ 12:00 pm - 1:00 pm Environmental Sciences and Engineering Centennial Seminar featuring Jordan Kern January 21, 2021 @ 12:00 pm - 1:00 pm View All Events Where would you like to go next? SEARCH THE SITE CORONAVIRUS PORTAL CONTACT US VISIT US APPLY DEGREES ONLINE PROGRAMS CENTERS AND INSTITUTES STUDENT RESOURCES FACULTY/STAFF RESOURCES UNC GILLINGS SCHOOL OF GLOBAL PUBLIC HEALTH 170 ROSENAU HALL, CB #7400 | 135 DAUER DRIVE | CHAPEL HILL, NC 27599‑7400